🆕 Project NextGen Request for Preliminary Proposal (RPP) opportunity under the RRPV | Rapid Response Partnership Vehicle: On-Demand Manufacturing. Building an end-to-end manufacturing capability that enables the production of medical countermeasures – whenever and wherever they are needed – is essential to pandemic preparedness and response. This RPP seeks to support the development of new manufacturing technologies that can produce vaccines and therapeutics on demand against COVID-19 and other health security threats. Project NextGen, led by BARDA and the National Institute of Allergy and Infectious Diseases (NIAID) is advancing vaccines and therapeutics that are more durable and effective across variants as well as enabling technologies that will together improve our fight against COVID-19 and transform our response to future health security threats. Learn more and submit your abstract by September 25: https://ow.ly/XPHp50T18sX
Biomedical Advanced Research and Development Authority (BARDA)
Government Administration
Washington, District of Columbia 19,749 followers
Advancing countermeasures against 21st century health threats. Part of HHS/ASPR. https://medicalcountermeasures.gov
About us
The Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID). BARDA enhances the nation's public health security and emergency preparedness by facilitating communication on innovative products and solutions between federal agencies and public stakeholders.
- Website
-
https://www.medicalcountermeasures.gov/
External link for Biomedical Advanced Research and Development Authority (BARDA)
- Industry
- Government Administration
- Company size
- 501-1,000 employees
- Headquarters
- Washington, District of Columbia
- Type
- Government Agency
- Founded
- 2006
Locations
-
Primary
400 7th St SW
Washington, District of Columbia 20024, US
Employees at Biomedical Advanced Research and Development Authority (BARDA)
-
Chris Houchens
-
Kim Sciarretta
Supervisory Biologist, Biomedical Advanced Research and Development Authority, Department of Health and Human Services
-
Ashley Cecere, M.S.
Special Assistant to the Director at Biomedical Advanced Research & Development Authority
-
Anna Wight ORourke
Senior Advisor - Clinical Research & Development for the Biomedical Advanced Research & Development Authority (BARDA)
Updates
-
Have an innovative technology and looking for partnership opportunities? Check out our new Partnering Page to find out more about BARDA funding opportunities, ways to connect, and many other resources: https://ow.ly/ibmJ50T1x8W
-
This #NationalImmunizationAwarenessMonth, we’re focusing on the potential of microneedle patch vaccines to improve public health preparedness. At BARDA, we’re dedicated to making vaccinations against high consequence pathogens more effective and accessible through multiple delivery methods. Through Project NextGen and our DRIVe program, we’ve launched the Patch Forward Prize, a competition incentivizing patch-based vaccine innovation against COVID-19, seasonal influenza, and pandemic influenza. Learn more: https://ow.ly/cSP450T2hYX
-
Vaccines play an important role in the health security of our nation. BARDA leads the development and procurement of vaccines against high consequence pathogens that may not otherwise have commercial markets, such as pandemic influenza and Ebola. We’re observing #NationalImmunizationAwarenessMonth by highlighting our efforts to make vaccines more accessible and effective by advancing alternative vaccine delivery methods. From microneedle patches to pills you can swallow or nasal sprays, alternative delivery technologies have the potential to enhance pandemic preparedness against infectious diseases by: ➡️ Improving Ease of Administration: User-friendly and accessible technologies are especially important for people that are needle-adverse and can also reduce the training needed to give vaccines, which would enable first responders to more easily administer those vaccines in an emergency ➡️ Enhancing Vaccine Stability, Storage and Distribution: Innovations like vaccine patches could reduce the need for cold-chain infrastructure, which will increase sustainability, reduce storage costs, and broaden our ability to distribute vaccines across different communities ➡️ Promoting Robust Immune Responses: Nasal and oral vaccines could improve vaccine effectiveness by stimulating a localized immune response at the site of infection Learn more about opportunities to partner with us on these initiatives: https://ow.ly/c5t950T29ss
-
There’s another chance to submit to DRIVe’s Agnostic Diagnostics program! We’re seeking proposals to advance metagenomic next generation sequencing (mNGS) technology as a diagnostic tool to counter any infectious disease threat. DRIVe is looking for partners to advance technology development in three areas: - Sequencing hardware that is accurate, portable, and cost-effective - Integrated sample preparation and assay components that improve protocol speed, and efficiency - Bioinformatic analysis tools that are user-friendly, automated, platform-agnostic, and support clinical interpretation This R&D funding opportunity is Area of Interest 26, which is described in amendment 23. The deadline to submit is 12 p.m. ET September 30, 2024. Submit early! Proposals are reviewed on a rolling basis. To learn more: https://ow.ly/nY1t50RRHzx
-
🆕 Project NextGen Request for Preliminary Proposal (RPP) opportunity under the RRPV | Rapid Response Partnership Vehicle: On-Demand Manufacturing. Building an end-to-end manufacturing capability that enables the production of medical countermeasures – whenever and wherever they are needed – is essential to pandemic preparedness and response. This RPP seeks to support the development of new manufacturing technologies that can produce vaccines and therapeutics on demand against COVID-19 and other health security threats. Project NextGen, led by BARDA and the National Institute of Allergy and Infectious Diseases (NIAID) is advancing vaccines and therapeutics that are more durable and effective across variants as well as enabling technologies that will together improve our fight against COVID-19 and transform our response to future health security threats. Learn more and submit your abstract by September 25: https://ow.ly/XPHp50T18sX
-
On August 13, BARDA experts attended the ribbon cutting of our partner TriLink BioTechnologies, part of Maravai LifeSciences. Our $38M investment supported the construction of this facility, which will be a key site for manufacturing nucleic acid raw materials in San Diego, CA. These raw materials are key to producing mRNA-based vaccines and therapeutics. BARDA is focused on improving the nation’s critical biopharmaceutical supply chain. mRNA technology has the potential to fill the gap in vaccine and therapeutic manufacturing in preparation for public health emergencies. This milestone demonstrates the power of public-private partnerships. When we work together, we can achieve more to improve and strengthen the health security of our nation. Learn more about this work and other domestic manufacturing, industrial base expansion, and capacity strengthening efforts: https://ow.ly/U3Bx50SYQ0m
-
We are excited to announce that the Concept Stage for the #PatchForwardPrize is now open and accepting submissions! The $50 million competition under #ProjectNextGen is to advance microneedle patch-based RNA vaccines for #COVID19, seasonal #flu, and pandemic flu. Vaccine developers and patch makers are encouraged to partner and accelerate new vaccine technologies. Concept papers should detail respective technologies, which includes the proposed vaccine and delivery product, and plans for development and functional testing. Submissions are due no later than October 3, 2024, 4:59 p.m. ET. Get started on your submission by visiting: https://ow.ly/Hbyg50SYRwF.
-
Our Regulatory Affairs team provides guidance to facilitate development and FDA approval/licensure/clearance of safe, effective medical countermeasures. Liaising with our specialists and other government agencies, Regulatory Affairs interprets regulatory policies and advises on best practices for BARDA programs. Learn more: https://ow.ly/YtLr50SXIhb
-
The NxTAG Respiratory Pathogen Panel v2, a combination test from partner Diasorin that was developed with BARDA support, recently received FDA 510(k) clearance. This improved multiplexed PCR test detects 21 common viral and bacterial pathogens that cause respiratory illness, including COVID-19. With this test, clinicians will be able to rapidly detect and differentiate among the most common pathogens that cause respiratory illness and provide life-saving treatment to patients. This latest clearance supports national preparedness by leveraging existing platforms that can be rapidly adapted to emerging threats. Learn more: https://ow.ly/7fSX50SYtW3